Sushmita Panda is a Global Pharma Reporter at Scrip. She covers a range of topics within the realms of medicine and healthcare, with a particular focus on pharmaceuticals, healthcare technology, and wellness. Sushmita's insights and expertise have been featured in Financial Express (India), Citeline, and Scrip.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Sushmita’s coverage revolves around healthcare and pharmaceuticals, with a strong emphasis on data-driven reporting and government announcements. Given her focus, she would likely be interested in pitches from experts who can provide analysis or commentary on the latest developments in the Indian healthcare sector, including topics such as drug approvals, medical research, and COVID-19.
As Sushmita heavily relies on data for her articles, providing statistical insights or access to new research findings may increase the chances of grabbing her attention. Additionally, given the local (India) geographic focus of her work alongside references to specific governmental meetings and alerts issued by regulatory bodies like CDSCO (Central Drugs Standard Control Organization), sources with knowledge of India's healthcare policies and regulations are likely to be valuable for pitching relevant stories.
Her articles also cover scientific themes; therefore pitches geared towards recent breakthroughs in medical research could resonate well with Sushmita's coverage scope.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The biotech is eyeing a 2027 start for divesiran's Phase III trial as it plays catch-up to Takeda and Protagonist's rusfertide.
By: Sushmita Panda
The decision puts the spotlight on the bispecific's remaining Phase III program across cervical cancer, head and neck cancer and mesothelioma.
By: Sushmita Panda
Insilico's new platform combines AI, aging biology and virtual-cell modeling to support drug discovery.
By: Sushmita Panda
Regeneron's latest pipeline setback puts fresh focus on its remaining ophthalmology bets and the broader slate of clinical catalysts that will shape its growth outlook.
By: Sushmita Panda
The FDA's approval decision date on Capricor's deramiocel has shifted to November, but questions remain over whether fresh long-term HOPE-3 data and a refined upper-limb indication will be enough to convince the agency.
By: Sushmita Panda
The focus will now shift to launch uptake, competitive displacement and whether the drug can establish itself across a broader HER2 franchise.
By: Sushmita Panda
Lilly inks its 13th acquisition of 2026 with a deal for Merida Biosciences and its Phase I antibody-degrader.
Moderna's melanoma data have strengthened the case for mRNA in cancer, but developers are now testing how far the technology can extend across rare diseases, respiratory medicine and cell therapy.
The drug's next test will be whether full data can translate a headline Phase III win into a meaningful position in the crowded BTK market where liver safety will be crucial.
AstraZeneca's Baxfendy approval has opened the door for aldosterone synthase inhibitors in hypertension, and Mineralys's lorundrostat could be the next one through.
